Toggle navigation
Toggle navigation
化学合成
生命科学
分析化学与色谱
结构式检索
分类目录
价格折扣
Excel/SDF文件处理
×
搜索结果
MolSoft
Ketcher
ChemDraw
同时返回
精确结构检索
、
子结构(亚结构)检索
、
相似结构检索
结果。
同时返回
精确结构检索
、
子结构(亚结构)检索
、
相似结构检索
结果。
同时返回
精确结构检索
、
子结构(亚结构)检索
、
相似结构检索
结果。
显示chemdraw
Medical Research Areas
Angiogenesis
PDGFR
PDGFR
下级目录
TAK-593
SIM010603
SKLB610
Henatinib
PD089828
3-[2,4-dimethyl-5-[(E)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
AAL-993
Crenolanib
XL999
N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide
R1530
AZD-2932
LY2457546
3-[(3-(2-Carboxyethyl)-4-methylpyrrol-2-YL)methylene]-2-indolinone
Axitinib
Masitinib
木利替尼
1-(2,4-Difluorophenyl)-3-(4-(6,7-dimethoxyquinolin-4-yloxy)-2-fluorophenyl)urea
5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfonamide
PD-166866
瑞格非尼
目录项下的产品
1005780-62-0 / MFCD105780620
TAK-593 is a n oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation.
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
1032265-67-0 / MFCD132265670
SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC(50) values between 5.0 and 68.1 nmol/l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis.
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
1125780-41-7 / MFCD20261423
N-Methyl-4-(4-(3-(Trifluoromethyl)Benzamido)Phenoxy)Picolinamide
N-甲基-4-(4-(3-(三氟甲基)苯甲酰氨基)苯氧基)吡啶-2-甲酰胺
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
1239269-51-2 / MFCD339269512
Henatinib maleate is t he maleate salt form of henatinib, an orally bioavalable, multitargeted tyrosine kinase inhibitor with potential antitumor and antiangiogenic activities. Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
179343-17-0 / MFCD79343170
PD089828
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
252916-29-3 / MFCD52916293
3-[2,4-dimethyl-5-[(E)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
269390-77-4 / MFCD69390774
AAL-993 is a highly potent inhibitor of VEGFR-1 (IC50 =130nM), VEGFR-2 (IC50=23nM) and VEGFR-3 (IC50=18nM). At higher concentrations it inhibits PDGFR-β (640nM), c-Kit (236nM) and CSF-1R (380nM).
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
670220-88-9 / MFCD70220889
1-[2-[5-[(3-Methyl-3-Oxetanyl)Methoxy]-1-Benzimidazolyl]-8-Quinolyl]-4-Piperidinamine
[1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
705946-27-6 / MFCD05946276
(Z)-5-((1-Ethylpiperidin-4-Yl)Amino)-3-((3-Fluorophenyl)(5-Methyl-1H-Imidazol-2-Yl)Methylene)Indolin-2-One
(Z)-5-((1-乙基哌啶-4-基)氨基o)-3-((3-氟苯基)(5-甲基-1H-咪唑-2-基)亚甲基)吲哚啉-2-酮
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
850879-09-3 / MFCD50879093
N-(Benzo[D][1,3]Dioxol-5-Ylmethyl)-4-(Benzofuro[3,2-d]Pyrimidin-4-Yl)Piperazine-1-Carbothioamide
N-(苯并[d][1,3]二氧杂环戊烷-5-基甲基)-4-(苯并呋喃并[3,2-d]嘧啶-4-基)哌嗪-1-甲硫酰胺
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
882531-87-5 / MFCD82531875
R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta‚ FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
883986-34-3 / MFCD83986343
AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR. AZD-2932 has a balanced ~ 1:1 ratio of activity vs both VEGFR-2 and PDGFRβ and shows IC50 values of 8 and 4 nM against the two enzymes, respectively. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. The pharmacokinetic behavior and the preclinical antitumor activity in nude mice bearing C6 rat glial tumors indicate that 31 has the potential to become an antiangiogenic agent in the clinic.
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
908265-94-1 / MFCD008265941
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 syngeneic rat mammary tumor models. Additionally, LY2457546 caused complete regression of well-established tumors in an acute myelogenous leukemia (AML) FLT3-ITD mutant xenograft tumor model. The unique spectrum of target activity, potent in vivo anti-tumor efficacy in a variety of rodent and human solid tumor models, exquisite potency against a clinically relevant model of AML, and non-clinical safety profile justify the advancement of LY2457546 into clinical testing. (source: Invest New Drugs. 2012
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
215543-92-3 / MFCD08235144
SU5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μ M at VEGFR2, FGFR1, PDGFR β and EGFR respectively).
SU5402
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
319460-85-0 / MFCD09837898
Axitinib
阿西替尼
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
中华人民共和国
√
790299-79-5 / MFCD09954132
Masitinib, also known as AB1010, is an orally bioavailable and multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs). Masitinib was approved for veterinary use.
马塞替尼
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
中华人民共和国
366017-09-6 / MFCD09954135
Mubritinib
木利替尼
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
√
228559-41-9 / MFCD09971092
1-(2,4-difluorophenyl)-3-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-fluorophenyl)urea
1-(2,4-二氟苯基)-3-(4-((6,7-二甲氧基喹啉-4-基)氧基)-2-氟苯基)脲
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
√
444731-52-6 / MFCD11616589
Pazopanib
帕唑帕尼
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
中华人民共和国
√
192705-79-6 / MFCD12922514
1-(2-Amino-6-(3,5-Dimethoxyphenyl)Pyrido[2,3-D]Pyrimidin-7-Yl)-3-(Tert-Butyl)Urea
1-(2-氨基-6-(3,5-二甲氧基苯基)吡啶并[2,3-d]嘧啶-7-基)-3-(叔丁基)脲
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
755037-03-7 / MFCD16038047
4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[[4-氯-3-(三氟甲基)苯基]氨基甲酰]氨基]-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺
原料
0
资源
0.0
询
0.0
%成交
交易量
试剂
中华人民共和国
√